Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02383433
Title Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

pancreatic adenocarcinoma

Therapies

Gemcitabine + Regorafenib

Age Groups: adult
Covered Countries USA


No variant requirements are available.